Tg Therapeutics, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
NASDAQ
TG Therapeutics announces significant revenue increase driven by BRIUMVI sales and positive clinical trial data for subcutaneous formulation and azer-cel.
NASDAQ
TG Therapeutics refinanced its debt with a new $750 million credit facility, adding $500 million in non-dilutive capital, and increased its share repurchase program to $300 million, while reporting strong Q1 2026 revenue growth.
NASDAQ
TG Therapeutics announced a significant increase in product revenue and net income for the nine months ended September 30, 2025, driven by strong BRIUMVI sales and a substantial tax benefit.
NASDAQ
TG Therapeutics reported significant revenue growth and a return to profitability in Q2 2025, driven by strong BRIUMVI sales and pipeline advancements.
NASDAQ
TG Therapeutics achieves profitability in Q1 2025, driven by strong sales of BRIUMVI, its multiple sclerosis treatment.
NASDAQ
TG Therapeutics reports a profitable third quarter in 2024, driven by strong Briumvi sales and strategic licensing agreements, while also highlighting ongoing clinical development programs.
NASDAQ
TG Therapeutics reports a profitable second quarter driven by strong Briumvi sales and secures a new $250 million credit facility.
NASDAQ
TG Therapeutics' first quarter 2024 results show significant revenue growth driven by Briumvi sales and a milestone payment, alongside increased R&D spending.